BRAF and colorectal carcinoma: Patients without RAS or RAF mutations profit from anti‐EGFR antibody therapy (Karapetis et al, 2008; Van Cutsem et al, 2009), while patients with BRAF‐mutant CRC now receive first‐line therapy combinations of anti‐EGFR antibodies and BRAF kinase inhibitors (Corcoran et al, 2018).